EPISODE 7- The Hidden Cost of Price Control Policies

In this episode, we interview Kirsten Axelsen, Senior Advisor at Charles Rivers Associates, about what would change in biopharma if price controls were implemented.

---

09.21.2021

The price control policies that are being discussed in Congress have the potential to harm innovation in the life science industry. But how, exactly?

In this episode, we interview Kirsten Axelsen, Senior Advisor at Charles Rivers Associates, about what would change in biopharma if price controls were implemented.

In this episode, we discuss:

• The close relationship between economy and drug development
• The U.S.’s role in developing over 40% of the world’s new medicines
• The potential reduction of biopharma global revenues by 19%
• What it means globally when 8-15 fewer medicines are made per decade
• Some flaws in the health technology assessment (HTI) regarding clinical trials

Incubate Policy Lab is the research arm of Incubate Coalition, where we will be releasing reports, whitepapers, and hosting events in partnership with Charles Richards Associates.

Listen on Apple, Spotify, Google, or your preferred podcast streaming platform.